glp-1 receptor agonists and sglt2 inhibitors Frontiers Frontiers | GLP−1 receptor agonists

Henney 2024) demonstrated a potentially meaningful reduction in incident pneumonia with GLP-1 RAs compared with dipeptidyl peptidase-4 (DPP-4) inhibitors (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.580.62

Background: The evidence on berberine stimulating the secretion of GLP-1 in intestinal L cell has been studied

In partnership with KFF Health News, NBCs Anne Thompson reports for TODAY.

GLP-1 therapies reduce inflammation across organs through rapid, weight-independent immune and metabolic effects.

Study results: what did they find

Obesity and Type 2 Diabetes has an increasing prevalence worldwide, presenting a major health challenge